The Cost of GLP-1 Drugs on Payers’ Minds as Nearly 1/3rd of U.S. Consumers Could Become Users

Health Populi August 7, 2024
Jane Sarasohn-Kahn

With 70 different clinical trials for GLP-1 drugs in process with the FDA, payers — and other stakeholders in the health care ecosystem — have the semaglutide-SENSE top of mind, based on my ongoing updating of this fast-moving market space.

For overall market context on pace-of-growth in adoption, check out this chart from a JAMA Health Forum research letter on Prescription Fills for Semaglutide Products by Payment Method, published August 2nd.

The study was based on the IQVIA National Prescription Audit PayerTrak data which captures 92% of Rx’s filled at retail pharmacies in the U.S. The bar and line chart here shows the trajectory of 3 GLP-1s from January 2021 to the end of 2023: Ozempic, by far the most-prescribed...

Today's Sponsors

Today's Sponsor